Cervical cancer
Conditions
Interventions
Experiment 1:Chemoradiotherapy in combination with nimotuzumab 100 mg weekly
Experiment 2:Chemoradiotherapy in combination with nimotuzumab 200 mg weekly
Experiment 3:Chemoradiotherapy in combination with nimotuzumab 400 mg weekly
Sponsors
Chengdu Fifth People's Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-75 years old 2. Pathological diagnosis of cervical squamous cell carcinoma or adenocarcinoma, adenosquamous carcinoma 3. FIGO 2018 Staging IIB~IIIC 4. Confirmed by two gynecologists with higher deputy senior titles as inoperable 5. Have sufficient liver, kidney and bone marrow function before the start of the study 6. Physical condition score ECOG0-1 points 7. Estimated survival time> 6 months
Exclusion criteria
Exclusion criteria: 1. Pregnant and lactating patients 2.Have had other malignancies within 5 years (except completely cured carcinoma in situ or basal cell or cutaneous squamous cell carcinoma) 3. Those who have participated in other drug clinical trials or medical device trials within 1 month before starting treatment 4. Those with a history of severe allergies or specific constitutions 5. The investigator judges that it is not suitable to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor size; | — |
Countries
China
Contacts
Public ContactHelang
Chengdu Fifth People's Hospital
Outcome results
None listed